GRADE Study (The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study)

The purpose of the study, conducted by the University of Alabama at Birmingham, Department of Nutrition Sciences, is to find the best combination drug treatment for diabetes.

Have you had Type 2 Diabetes less than 10 years? Is metformin the only Diabetes medication you are taking? Are you willing to take a second Diabetes drug? If so, you may be able to participate in a clinical research study that is trying to find the best combination drug treatment for type 2 Diabetes. Diabetes medications, visits, and lab tests will be provided free of charge.

Please call the following numbers for more information 205-996-4015, 205-996-4020 or 205-975-8217.

 

Novo Nordisk: Dose-finding of semaglutide administered subcutaneously once daily versus placebo and liraglutide in subjects with type 2 diabetes

The University of Alabama at Birmingham, Department of Nutrition Sciences, is conducting a 26 week research study to evaluate the effectiveness of an investigational drug to treat Type 2 DM.

The purpose of this trial is to investigate the safety, effectiveness and tolerability of a gluc ose-lowe ring product called “semaglutide” when injected once- daily. In this trial you will receive semaglutide, liraglutide or placebo. To qualify, you must be 19 years old or older, Type 2 Diabetes and on Metformin or diet and exercise only to control your blood sugars. Qualified participants will receive study drug, diet/exercise counseling, EKG, Physical and diabetic supplies. There is no charge for participation. Compensation for time and travel may also be available.

Please call the following numbers for more information 205-996-4015 or 205-996-4020.

 

Elcelyx Therapeutics, Inc.: A randomized, double-blind, parallel-group, multicenter, placebo-controlled, dose-ranging study to evaluate the glycemic effects, safety, and tolerability of metformin delayed-release in subjects with type 2 diabetes mellitus

The purpose of the present study is to compare the glycemic effects of Met DR to placebo in subjects with T2DM at 16 weeks. The study is designed to evaluate several doses of Met DR compared to placebo. A single-blind reference treatment of 2000 mg Met IR per day administered as equal divided doses (1000 mg Met IR BID) will also be included. To qualify, you must be 25 years old or older, diagnosed with Type 2 Diabetes, being treated with diet and exercise alone, or are taking certain other anti-diabetic medications. Qualified participants will receive study drug, study-related laboratory testing, diet/exercise counseling, EKG, Physical and diabetic supplies. There is no charge for participation. Compensation for time and travel may also be available. For more information, and to see if you might be eligible to join, please contact (205)975-8217 or (205)996-4020.